IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
From the first launch to ongoing market access execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We are the data and application backbone for market access departments of Life Sciences manufacturers, enabling them to accelerate their commercialization process, digitalize their operations, and get therapies to patients faster.
Solutions overview
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Traditionally, the pharmaceutical industry has monitored purchase orders for unusual sizes and patterns. Manufacturers should continue this practice as part of compliance and risk monitoring. However, there are notable gaps when exclusively relying on the traditional approach.
A comprehensive solution must also monitor and potentially report whether individual pharmacies are over procuring Schedule 2 drugs. Enriched 867 data provides complete visibility to all ordering at the individual ship-to location level across wholesalers and distributors.
In addition to capturing the size and frequency of orders, IntegriChain can enhance the accuracy of monitoring and reporting suspicious orders at the pharmacy by including the following metrics:
